CYTO 2019 Workshop: Assuring Rigor and Reproducibility for use of Mass Cytometry in Clinical Research
The addition of mass cytometry to the pool of technologies in clinical studies requires more standardization and quality control. Discussion on the use of CyTOF assays for clinical research including panel design and validation, reagents and protocols for sample processing, instrument operation, quality control, regulatory oversight and data analysis is needed. We hope to bring together experts in the field at CYTO 2019 to learn from their experiences and discuss how best to overcome these challenges.
1. Are you currently using Mass Cytometry? More than one response can be selected.
2. If you are currently NOT using Mass Cytometry, what is preventing you from using this technology? More than one response can be selected.
3. What type of clinical studies/research do you use Mass Cytometry for? More than one response can be selected.
4. Which area(s) in the CyTOF workflow do you struggle with? More than one response can be selected.
5a. Regarding experimental design, what are the main challenges you have encountered? More than one response can be selected.
5b. How have you attempted to solve these main challenges?
Your answer
6a. Regarding reagent availability, what are the main challenges you have encountered? More than one response can be selected
6b. How have you attempted to solve these main challenges?
Your answer
7a. Regarding protocol optimization, what are the main challenges you have encountered? More than one response can be selected.
7b. How have you attempted to solve these main challenges?
Your answer
8a. Regarding panel design and validation, what are the main challenges you have encountered? More than one response can be selected.
8b. How have you attempted to solve these main challenges?
Your answer
9a. Regarding sample processing, what are the main challenges you have encountered? More than one response can be selected.
9b How have you attempted to solve these main issues?
Your answer
10a. Regarding instrumentation, what are the main challenges you have encountered? More than one response can be selected.
10b. How have you attempted to solve these main challenges?
Your answer
11a. Regarding quality control, what are the main challenges you have encountered? More than one response can be selected.
11b. How have you attempted to solve these main challenges?
Your answer
12. Regarding software/data analysis and statistical evaluation, what are the main challenges you have encountered? More than one response can be selected.
12b. How have you attempted to solve these main challenges?
Your answer
13. Regarding industry regulation, what are the main challenges you have encountered? More than one response can be selected.
14. How do you typically account for batch effects with CyTOF data?
15. What platform do you use for CyTOF data analysis?
16. Do you think CyTOF is mature enough to be used in clinical trials?
Submit
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service